# US 2025/0367169 A1 · Formulations for personalized methods of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367169 A1
- Document ID: US20250367169A1
- Status: Published application
- Kind: A1
- Application number: 19/003,692
- Filed: 2024-12-27
- Published: 2025-12-04
- Earliest claimed: 2020-06-03
- Assignees: Faeth Therapeutics, Inc.
- Applicants: Faeth Therapeutics Inc
- Inventors: Oliver D.K. Maddocks
- Web page: https://patentgrep.com/patent/US20250367169A1

## CPC

- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A23L 33/15: Vitamins
- A23L 33/175: Amino acids
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are formulations and methods of administering formulations to starve cells of nutrients, such as amino acids. The formulations of the present invention can be substantially be devoid of one or more non-essential amino acids.

## Claims

### Claim at position 1

1-43. (canceled)

### Claim 44

A composition for treating a patient with cancer comprising in unit dosage form:
a) a non-essential amino acid comprising alanine or a salt thereof in an amount from about 4% to about 8% (w/w), wherein the non-essential amino acid or the salt thereof is not part of a polypeptide;
b) a first essential amino acid comprising lysine or a salt thereof in an amount from about 8% to about 12% (w/w) and a second essential amino acid comprising leucine or a salt thereof in an amount from about 6% to about 11% (w/w), wherein the first essential amino acid or the salt thereof and the second essential amino acid or the salt thereof are not part of a polypeptide; and
c) a pharmaceutically acceptable excipient,
wherein the composition is devoid of proline and salts thereof.

### Claim 45 (depends on 44)

The composition of claim 44, further comprising a third essential amino acid or a salt thereof, wherein the third essential amino acid or the salt thereof is present in the composition in a different amount from the first essential amino acid or the salt thereof and the second essential amino acid or the salt thereof.

### Claim 46 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of serine and salts thereof.

### Claim 47 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of glycine and salts thereof.

### Claim 48 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of serine and salts thereof and glycine and salts thereof.

### Claim 49 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of cysteine and salts thereof.

### Claim 50 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of cysteine and salts thereof, serine and salts thereof, and glycine and salt thereof.

### Claim 51 (depends on 44)

The composition of claim 44, wherein the unit dosage form has a weight of about 10 grams to about 20 grams.

### Claim 52 (depends on 44)

The composition of claim 44, wherein the unit dosage form has a weight of about 16 grams.

### Claim 53 (depends on 44)

The composition of claim 44, wherein the composition is in a powder form.

### Claim 54 (depends on 44)

The composition of claim 44, wherein the composition further comprises from about 2% to about 5% (w/w) of a K+ source.

### Claim 55 (depends on 54)

The composition of claim 54, wherein the K+ source comprises potassium citrate, potassium phosphate, potassium chloride, potassium sulfate, potassium gluconate, potassium bicarbonate, potassium aspartate, potassium acetate, potassium orotate, or a hydrate thereof.

### Claim 56 (depends on 44)

The composition of claim 44, wherein the composition further comprises from about 1% to about 4% (w/w) of a Mg2+ source.

### Claim 57 (depends on 56)

The composition of claim 56, wherein the Mg2+ source comprises magnesium citrate, magnesium fumarate, magnesium acetate, magnesium aspartate, magnesium threonate, magnesium glycinate, magnesium chloride, magnesium sulfate, magnesium oxide, magnesium malate, magnesium orotate, or a hydrate thereof.

### Claim 58 (depends on 44)

The composition of claim 44, wherein the composition further comprises taurine, a hydrate thereof, or a salt thereof from about 0.05% to about 2% (w/w).

### Claim 59 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of glutamine and salts thereof.

### Claim 60 (depends on 44)

The composition of claim 44, wherein the composition is further devoid of glutamine and salts thereof and cysteine and salts thereof.

### Claim 61 (depends on 44)

The composition of claim 44, wherein the composition further comprises a flavorant.

### Claim 62 (depends on 44)

The composition of claim 44, wherein the composition further comprises a sweetener.
